Key result
Five novel plasma proteins are linked to long-term incident heart failure risk in diabetes.
Why the study?
Does plasma proteomic profiling identify specific biomarkers uniquely associated with the development of heart failure in individuals with diabetes?
Cohort (n=10,189)
Yes
Does plasma proteomic profiling identify specific biomarkers uniquely associated with the development of heart failure in individuals with diabetes?
p-value: p=<10^-5
The discovery of unique plasma proteins and inflammatory pathways associated with heart failure in diabetes provides mechanistic insights and highlights potential novel therapeutic targets for this high-risk population.
BACKGROUND: To investigate the proteomic signatures of heart failure (HF) in diabetes. The underlying mechanisms of the elevated risk of HF in diabetes are unknown. METHODS: In 10 189 ARIC study (Atherosclerosis Risk in Communities) participants free of HF (mean age 57±7 years, 56% women, 22% Black adults, 14% with diabetes), we conducted discovery and internal validation for the associations of 4955 plasma proteins with HF by diabetes status. We performed (1) Cox regression to identify proteins associated with HF by diabetes status, (2) external validation in the MESA study (Multi-Ethnic Study of Atherosclerosis, n=5233, 633 with diabetes), and (3) pathway analyses for identified proteins. RESULTS: Over 24 years in ARIC, there were 2417 HF events (605 among individuals with diabetes). In 993 individuals with diabetes in the discovery sample, 19 proteins were associated with HF ( P <10 –5 ), 12 proteins replicated in the internal validation sample ( P <0.05/19). Six of the internally validated proteins replicated in MESA (false discovery rate, q<0.05). Five proteins were specifically associated with HF in those with diabetes: 4 are novel (inactive tyrosine-protein kinase 7, chondroadherin, leucine-rich repeat, and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 and fibulin-5) and 1 is the previously known (cartilage intermediate layer protein 2). NPPB (N-terminal pro-BNP) was associated with HF in those with and without diabetes. Pathways over-represented among proteins associated with diabetes-related HF were lipid metabolism, inflammation, and brown adipose tissue (false discovery rate, q<0.05). CONCLUSIONS: We identified 5 proteomic markers (4 novel) uniquely related to HF risk among individuals with diabetes and not among those without diabetes.
No takes yet. Share an insight, caveat, or question.
Echouffo‐Tcheugui et al. (2026) conducted a cohort in Heart failure in diabetes (n=10,189). Plasma proteomic signatures (4,955 proteins) vs. Individuals without diabetes was evaluated on Incident heart failure (first hospitalization or death related to HF) (p=<10^-5). Five plasma proteins (PTK7, CHAD, LINGO1, FBLN5, and CILP2) were uniquely associated with incident heart failure risk among individuals with diabetes over a median 24-year follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: